Viridian Therapeutics Inc (NASDAQ:VRDN)

Delayed Data
As of Sep 23
 +0.39 / +2.79%
Today’s Change
Today|||52-Week Range

Stock Price Forecast

The 6 analysts offering 12-month price forecasts for Viridian Therapeutics Inc have a median target of 35.00, with a high estimate of 44.00 and a low estimate of 26.00. The median estimate represents a +142.38% increase from the last price of 14.44.

Analyst Recommendations

The current consensus among 6 polled investment analysts is to Buy stock in Viridian Therapeutics Inc. This rating has held steady since August, when it was unchanged from a Buy rating.Move your mouse over past
months for detail


Earnings and Sales Forecasts

Current Quarter

Earnings per Share
Reporting Date
Nov 10

Earnings per Share

Move your mouse over a quarter or year to see how estimates have changed over time.

Growthquarterly 50.23%
Growthannually 82.54%


Growthquarterly -58.33%
Growthannually 232.59%
Key to the earnings and sales forecast charts.